Tags

Type your tag names separated by a space and hit enter

Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study.
Andrology. 2017 07; 5(4):771-775.A

Abstract

Several intralesional therapeutic protocols have been proposed for the treatment of Peyronie's disease. Among all, hyaluronic acid (HA) and verapamil have been differently tested. We aimed to evaluate the efficacy of intralesional verapamil (ILVI) compared with intralesional HA in patients with early onset of Peyronie's disease (PD). This is a multi-centre prospective double-arm, randomized, double-blinded study comparing ILVI vs. intralesional HA after 12-weeks. Sexually active men, older than 18 years and affected by the acute phase of PD were eligible for this study. Patients have been double-blinded randomly divided into two groups (1 : 1 ratio): Group A received intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks, while group B received intralesional treatment with HA (0.8% highly purified sodium salt HA 16 mg/2 mL) weekly for 12 weeks. The primary efficacy outcome was the change from the baseline to the endpoint (12 weeks after therapy) for the penile curvature (degree). The secondary outcome was the change in the plaque size and in the International Index of erectile Function (IIEF-5) score. The difference between post- and pre-treatment plaque size was -1.36 mm (SD ± 1.27) for Group A and -1.80 mm (SD ± 2.47) for Group B (p-value = NS). IIEF-5 increased of 1.46 points (SD ± 2.18) in Group A and 1.78 (SD ± 2.48) in Group B (p-value ± NS). No difference in penile curvature was observed in Group A, while in Group B the penile curvature decreased of 4.60° (SD ± 5.63) from the baseline (p < 0.001) and vs. Group A. According to PGI-I results, we found significant difference as concerning patient global impression of improvement (PGI-I) (4.0 vs. 2.0; p < 0.05). This prospective, double-arm, randomized, double-blinded study comparing ILVI vs. HA as intralesional therapy showed greater efficacy of HA in terms of penile curvature and PGI-I.

Authors+Show Affiliations

Urology Section, Department of Surgery, University of Catania, Catania, Italy.Urology Section, Department of Surgery, University of Catania, Catania, Italy.Department of Urology and Andrology, University of Perugia, Perugia, Italy.Department of Urology, University of Sassari, Sassari, Italy.Urology Section, Department of Surgery, University of Catania, Catania, Italy.Urology Section, Department of Surgery, University of Catania, Catania, Italy.Department of Urology and Andrology, University of Perugia, Perugia, Italy.Urology Unit, Santa Chiara Regional Hospital, Trento, Italy.Medicitalia Andrology Section, Outpatient Clinic of Ferrara, Ferrara, Italy.Urology Unit, Cattinara Hospital, Trieste, Italy.Urology Unit, San Giacomo Hospital, Monopoli, Italy.Urology Unit, Hospital "degli Infermi", Biella, Italy.Urology Department, University "La Sapienza", Rome, Italy.Urology Department, University of Naples Federico II, Naples, Italy.Urology Department, University of Naples Federico II, Naples, Italy.Department of Statistics, University of Catania, Catania, Italy.Urology Department, University of Naples Federico II, Naples, Italy.Urology Section, Department of Surgery, University of Catania, Catania, Italy.

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

28718527

Citation

Favilla, V, et al. "Evaluation of Intralesional Injection of Hyaluronic Acid Compared With Verapamil in Peyronie's Disease: Preliminary Results From a Prospective, Double-blinded, Randomized Study." Andrology, vol. 5, no. 4, 2017, pp. 771-775.
Favilla V, Russo GI, Zucchi A, et al. Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. Andrology. 2017;5(4):771-775.
Favilla, V., Russo, G. I., Zucchi, A., Siracusa, G., Privitera, S., Cimino, S., Madonia, M., Cai, T., Cavallini, G., Liguori, G., D'Achille, G., Silvani, M., Franco, G., Verze, P., Palmieri, A., Torrisi, B., Mirone, V., & Morgia, G. (2017). Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. Andrology, 5(4), 771-775. https://doi.org/10.1111/andr.12368
Favilla V, et al. Evaluation of Intralesional Injection of Hyaluronic Acid Compared With Verapamil in Peyronie's Disease: Preliminary Results From a Prospective, Double-blinded, Randomized Study. Andrology. 2017;5(4):771-775. PubMed PMID: 28718527.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie's disease: preliminary results from a prospective, double-blinded, randomized study. AU - Favilla,V, AU - Russo,G I, AU - Zucchi,A, AU - Siracusa,G, AU - Privitera,S, AU - Cimino,S, AU - Madonia,M, AU - Cai,T, AU - Cavallini,G, AU - Liguori,G, AU - D'Achille,G, AU - Silvani,M, AU - Franco,G, AU - Verze,P, AU - Palmieri,A, AU - Torrisi,B, AU - Mirone,V, AU - Morgia,G, PY - 2016/11/28/received PY - 2017/03/03/revised PY - 2017/03/23/accepted PY - 2017/7/19/entrez PY - 2017/7/19/pubmed PY - 2018/1/30/medline KW - Peyronie's disease KW - hyaluronic acid KW - intralesional therapy KW - verapamil SP - 771 EP - 775 JF - Andrology JO - Andrology VL - 5 IS - 4 N2 - Several intralesional therapeutic protocols have been proposed for the treatment of Peyronie's disease. Among all, hyaluronic acid (HA) and verapamil have been differently tested. We aimed to evaluate the efficacy of intralesional verapamil (ILVI) compared with intralesional HA in patients with early onset of Peyronie's disease (PD). This is a multi-centre prospective double-arm, randomized, double-blinded study comparing ILVI vs. intralesional HA after 12-weeks. Sexually active men, older than 18 years and affected by the acute phase of PD were eligible for this study. Patients have been double-blinded randomly divided into two groups (1 : 1 ratio): Group A received intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks, while group B received intralesional treatment with HA (0.8% highly purified sodium salt HA 16 mg/2 mL) weekly for 12 weeks. The primary efficacy outcome was the change from the baseline to the endpoint (12 weeks after therapy) for the penile curvature (degree). The secondary outcome was the change in the plaque size and in the International Index of erectile Function (IIEF-5) score. The difference between post- and pre-treatment plaque size was -1.36 mm (SD ± 1.27) for Group A and -1.80 mm (SD ± 2.47) for Group B (p-value = NS). IIEF-5 increased of 1.46 points (SD ± 2.18) in Group A and 1.78 (SD ± 2.48) in Group B (p-value ± NS). No difference in penile curvature was observed in Group A, while in Group B the penile curvature decreased of 4.60° (SD ± 5.63) from the baseline (p < 0.001) and vs. Group A. According to PGI-I results, we found significant difference as concerning patient global impression of improvement (PGI-I) (4.0 vs. 2.0; p < 0.05). This prospective, double-arm, randomized, double-blinded study comparing ILVI vs. HA as intralesional therapy showed greater efficacy of HA in terms of penile curvature and PGI-I. SN - 2047-2927 UR - https://wwww.unboundmedicine.com/medline/citation/28718527/Evaluation_of_intralesional_injection_of_hyaluronic_acid_compared_with_verapamil_in_Peyronie's_disease:_preliminary_results_from_a_prospective_double_blinded_randomized_study_ L2 - https://doi.org/10.1111/andr.12368 DB - PRIME DP - Unbound Medicine ER -